Genmab A/S - Understand $gmab stock

$GMAB Market Cap: $122.5 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$18.97B

TTM

Gross Margin

96.8%

TTM

Net Earnings

$5.502B

TTM

Current Assets

$21.94B

Q2 2024

Current Liabilities

$4.364B

Q2 2024

Current Ratio

502.68%

Q2 2024

Total Assets

$38.62B

Q2 2024

Total Liabilities

$7.650B

Q2 2024

Book Value

$30.97B

Q2 2024

Cash

$4.331B

Q2 2024

P/E

22.27

Nov 29, 2024 EST

Free Cash Flow

$6.515B

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999
Revenue	$16.47B	$14.60B	$8.482B	$10.11B	$5.366B	$3.025B	$2.365B	$1.816B	$1.133B	$850.4M	$663.6M	$484.6M	$350.9M	$582.1M	$586.1M	$745.1M	$529.5M	$135.5M	$98.50M	$4.100M	$68.30M	$0.00	$0.00	$0.00	$0.00
YoY Change	12.87%	72.07%	-16.11%	88.43%	77.38%	27.89%	30.25%	60.29%	33.24%	28.15%	36.94%	38.1%	-39.72%	-0.68%	-21.34%	40.72%	290.77%	37.56%	2302.44%	-94.0%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999
Revenue	$16.47B	$14.60B	$8.482B	$10.11B	$5.366B	$3.025B	$2.365B	$1.816B	$1.133B	$850.4M	$663.6M	$484.6M	$350.9M	$582.1M	$586.1M	$745.1M	$529.5M	$135.5M	$98.50M	$4.100M	$68.30M	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue	$226.0M	$0.00	$0.00													$48.80M
Gross Profit	$16.25B	$14.51B	$8.417B													$696.3M
Gross Profit Margin	98.63%	99.38%	99.23%													93.45%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999
Selling, General & Admin	$3.252B	$2.638B	$1.266B	$651.0M	$339.0M	$212.0M	$146.5M	$102.3M	$90.97M	$79.14M	$66.20M	$63.60M	$168.1M	$310.5M	$148.7M	$143.5M	$117.5M	$94.70M	$84.70M	$72.00M	$64.60M	$86.80M	$54.90M	$16.40M	$2.200M
YoY Change	23.28%	108.37%	94.47%	92.04%	59.94%	44.65%	43.3%	12.4%	14.95%	19.55%	4.09%	-62.17%	-45.86%	108.81%	3.62%	22.13%	24.08%	11.81%	17.64%	11.46%	-25.58%	58.11%	234.76%	645.45%
% of Gross Profit	20.01%	18.19%	15.04%													20.61%
Research & Development	$7.575B	$5.346B	$4.004B	$2.937B	$2.250B	$1.345B	$805.0M	$620.1M	$461.2M	$493.7M	$516.5M	$522.6M	$416.6M	$403.8M	$935.4M	$1.423B	$849.2M	$513.1M	$441.7M	$373.3M	$346.0M	$396.2M	$195.7M	$61.20M	$16.70M
YoY Change	41.69%	33.52%	36.33%	30.53%	67.26%	67.11%	29.82%	34.45%	-6.59%	-4.41%	-1.17%	25.44%	3.17%	-56.83%	-34.26%	67.55%	65.5%	16.16%	18.32%	7.89%	-12.67%	102.45%	219.77%	266.47%
% of Gross Profit	46.62%	36.86%	47.57%													204.34%
Depreciation & Amortization	$295.0M	$362.0M	$248.0M	$259.0M	$139.0M	$87.60M	$69.75M	$40.96M	$31.82M	$12.33M	$11.70M	$15.10M	$15.00M	$21.00M	$83.80M	$85.10M	$14.30M	$17.50M	$31.80M	$53.70M	$63.70M	$47.50M	$34.50M	$19.80M	$7.800M
YoY Change	-18.51%	45.97%	-4.25%	86.33%	58.68%	25.59%	70.31%	28.7%	158.07%	5.39%	-22.52%	0.67%	-28.57%	-74.94%	-1.53%	495.1%	-18.29%	-44.97%	-40.78%	-15.7%	34.11%	37.68%	74.24%	153.85%
% of Gross Profit	1.82%	2.5%	2.95%													12.22%
Operating Expenses	$10.93B	$8.238B	$5.464B	$3.798B	$2.728B	$1.645B	$999.0M	$763.3M	$402.7M	$585.2M	$594.3M	$601.3M	$599.8M	$735.4M	$1.084B	$1.566B	$966.7M	$607.8M	$526.4M	$445.4M	$410.5M	$483.1M	$250.6M	$77.70M	$18.90M
YoY Change	32.64%	50.77%	43.87%	39.22%	65.85%	64.64%	30.89%	89.56%	-31.19%	-1.53%	-1.16%	0.25%	-18.44%	-32.16%	-30.79%	62.03%	59.05%	15.46%	18.19%	8.5%	-15.03%	92.78%	222.52%	311.11%
Operating Profit	$5.321B	$6.267B	$2.953B													-$870.0M
YoY Change	-15.09%	112.22%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999
Interest Expense	$316.0M	$678.0M	$965.0M	-$409.0M	$221.0M	$231.7M	-$280.5M	$77.38M	$27.15M	$32.17M	$4.000M	-$2.200M	$41.00M	$38.10M	$151.9M	-$91.70M	$55.60M	$30.40M	$37.00M				-$1.500M	$3.600M	$0.00
YoY Change	-53.39%	-29.74%	-335.94%	-285.07%	-4.61%	-182.61%	-462.41%	185.04%	-15.61%	704.22%	-281.82%	-105.37%	7.61%	-74.92%	-265.65%	-264.93%	82.89%	-17.84%					-141.67%
% of Operating Profit	5.94%	10.82%	32.68%
Other Income/Expense, Net										$0.00	-$7.800M	$4.800M	-$1.400M	$0.00	$4.200M	-$2.800M	-$1.800M	$3.600M	-$2.700M	$26.10M	$15.00M	$47.00M	$83.40M	$37.70M	$1.000M
YoY Change										-100.0%	-262.5%	-442.86%		-100.0%	-250.0%	55.56%	-150.0%	-233.33%	-110.34%	74.0%	-68.09%	-43.65%	121.22%	3670.0%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999
Pretax Income	$5.637B	$7.035B	$3.983B	$5.904B	$2.859B	$1.612B	$1.064B	$1.130B	$757.5M	$297.3M	$65.40M	-$114.1M	-$209.8M	-$122.4M	-$342.0M	-$964.5M	-$383.4M	-$438.2M	-$393.6M	-$415.2M	-$327.2M	-$479.0M	-$168.7M	-$36.40M	-$17.90M
YoY Change	-19.87%	76.63%	-32.54%	106.51%	77.36%	51.54%	-5.88%	49.2%	154.76%	354.66%	-157.32%	-45.61%	71.41%	-64.21%	-64.54%	151.56%	-12.51%	11.33%	-5.2%	26.89%	-31.69%	183.94%	363.46%	103.35%
Income Tax	$1.285B	$1.513B	$975.0M	$1.146B	$693.0M	$139.8M	-$39.83M	-$56.86M	-$5.986M	-$3.950M	-$4.800M	-$2.600M	$5.900M	$20.90M	$5.900M	$600.0K	$0.00	$0.00	$0.00	$0.00	-$100.0K	$300.0K	$0.00	$0.00	$0.00
% Of Pretax Income	22.8%	21.51%	24.48%	19.41%	24.24%	8.67%	-3.74%	-5.03%	-0.79%	-1.33%	-7.34%
Net Earnings	$4.352B	$5.522B	$3.008B	$4.758B	$2.166B	$1.472B	$1.104B	$1.187B	$763.5M	$301.3M	$112.4M	-$487.1M	-$596.4M	-$321.5M	-$1.011B	-$965.1M	-$383.4M	-$438.2M	-$393.6M	-$415.2M	-$327.1M	-$479.3M	-$168.7M	-$36.40M	-$17.90M
YoY Change	-21.19%	83.58%	-36.78%	119.67%	47.13%	33.4%	-7.04%	55.48%	153.41%	168.06%	-123.08%	-18.33%	85.51%	-68.19%	4.74%	151.72%	-12.51%	11.33%	-5.2%	26.93%	-31.75%	184.11%	363.46%	103.35%
Net Earnings / Revenue	26.42%	37.83%	35.46%	47.06%	40.37%	48.66%	46.65%	65.36%	67.39%	35.43%	16.94%	-100.52%	-169.96%	-55.23%	-172.46%	-129.53%	-72.41%	-323.39%	-399.59%	-10126.83%	-478.92%
Basic Earnings Per Share
Diluted Earnings Per Share	$66.02	$83.65	$45.54M	$72.22M	$34.04M	$23.73M	$17.77M	$19.22M	$13.05M	$5.350M	$2.166M	-$10.59M	-$13.28M	-$7.160M	-$22.51M	-$21.64M	-$8.733M	-$11.26M	-$12.58M	-$15.67M	-$14.35M	-$21.49M	-$7.739M	-$2.619M	-$3.255M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999
Cash & Short-Term Investments	$28.14B	$22.32B	$19.34B	$16.08B	$10.97B	$6.106B	$5.423B	$3.922B	$3.493B	$2.661B	$1.557B	$1.504B	$1.101B	$1.649B	$1.278B	$1.762B	$3.693B	$1.724B	$1.253B	$1.158B	$1.036B	$1.369B	$1.599B	$1.765B	$39.10M
YoY Change	26.03%	15.44%	20.27%	46.56%	79.67%	12.6%	38.27%	12.27%	31.3%	70.87%	3.54%	36.63%	-33.27%	29.09%	-27.49%	-52.29%	114.2%	37.62%	8.16%	11.84%	-24.32%	-14.41%	-9.39%	4414.07%
Cash & Equivalents	$14.87B	$9.893B	$8.957B	$7.260B	$3.552B	$532.9M	$1.348B	$307.0M	$874.0M	$359.1M	$168.1M	$67.00M	$65.20M	$101.0M	$460.7M	$70.00M	$131.8M	$429.1M	$381.3M	$419.6M	$308.9M	$252.9M	$165.9M	$38.20M	$39.10M
Short-Term Investments	$13.27B	$12.43B	$10.38B	$8.819B	$7.419B	$5.573B	$4.075B	$3.615B	$2.619B	$2.301B	$1.389B	$1.437B	$1.035B	$1.548B	$816.9M	$1.692B	$3.562B	$1.295B	$871.6M	$738.9M	$726.9M	$1.116B	$1.433B	$1.727B	$0.00
Other Short-Term Assets										$0.00	$0.00	$13.40M	$355.2M	$704.7M	$767.0M	$8.700M	$7.400M	$5.600M	$16.10M	$9.600M	$2.200M	$2.000M	$5.800M	$1.600M	$800.0K
YoY Change											-100.0%	-96.23%	-49.6%	-8.12%	8716.09%	17.57%	32.14%	-65.22%	67.71%	336.36%	10.0%	-65.52%	262.5%	100.0%
Inventory	$57.00M	$0.00												$0.00	$0.00	$34.60M					$0.00
Prepaid Expenses
Receivables	$4.947B	$5.910B	$3.367B	$2.463B	$2.990B	$1.327B	$579.0M	$975.7M	$174.7M	$105.8M	$136.0M	$136.7M
Other Receivables	$0.00	$143.0M	$31.00M	$249.0M	$0.00	$0.00	$57.69M	$0.00	$0.00	$0.00	$0.00	$0.00
Total Short-Term Assets	$33.14B	$28.38B	$22.74B	$18.79B	$13.96B	$7.433B	$6.059B	$4.898B	$3.668B	$2.766B	$1.693B	$1.654B	$1.517B	$2.419B	$2.156B	$1.967B	$3.918B	$1.771B	$1.323B	$1.192B	$1.067B	$1.384B	$1.646B	$1.793B	$40.90M
YoY Change	16.78%	24.81%	20.99%	34.6%	87.82%	22.67%	23.72%	33.53%	32.59%	63.4%	2.37%	9.03%	-37.31%	12.2%	9.63%	-49.8%	121.24%	33.83%	10.99%	11.69%	-22.88%	-15.91%	-8.22%	4284.35%
Property, Plant & Equipment	$1.641B	$1.322B	$975.0M	$736.0M	$414.0M	$161.5M	$113.4M	$32.19M	$28.81M	$25.68M	$22.70M	$26.00M	$32.40M	$41.40M	$60.20M	$977.9M	$40.20M	$31.30M	$44.20M	$57.40M	$73.20M	$88.20M	$50.80M	$4.400M	$500.0K
YoY Change	24.13%	35.59%	32.47%	77.78%	156.28%	42.44%	252.29%	11.74%	12.18%	13.15%	-12.69%	-19.75%	-21.74%	-31.23%	-93.84%	2332.59%	28.43%	-29.19%	-23.0%	-21.58%	-17.01%	73.62%	1054.55%	780.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$134.0M	$133.0M	$371.0M	$1.081B	$149.0M							$0.00	$0.00	$400.0K	$500.0K	$600.0K	$600.0K	$2.500M	$3.100M	$5.700M	$5.700M	$11.70M	$15.70M	$21.50M	$0.00
YoY Change	0.75%	-64.15%	-65.68%	625.5%									-100.0%	-20.0%	-16.67%	0.0%	-76.0%	-19.35%	-45.61%	0.0%	-51.28%	-25.48%	-26.98%
Other Assets	$212.0M	$252.0M	$264.0M	$177.0M	$139.0M	$386.4M	$296.9M	$125.0M	$6.342M	$5.685M	$7.200M	$3.700M	$5.400M	$13.30M	$4.600M	-$200.0K						$34.60M
YoY Change	-15.87%	-4.55%	49.15%	27.34%	-64.03%	30.14%	137.49%	1871.54%	11.56%	-21.04%	94.59%	-31.48%	-59.4%	189.13%	-2400.0%
Total Long-Term Assets	$2.150B	$1.901B	$1.891B	$2.352B	$1.183B	$1.028B	$543.5M	$340.6M	$234.7M	$100.3M	$38.50M	$39.10M	$47.60M	$62.20M	$65.20M	$1.292B	$40.80M	$33.70M	$47.20M	$79.70M	$112.7M	$199.1M	$165.8M	$152.9M	$42.40M
YoY Change	13.1%	0.53%	-19.6%	98.82%	15.08%	89.13%	59.58%	45.15%	133.89%	160.59%	-1.53%	-17.86%	-23.47%	-4.6%	-94.95%	3067.16%	21.07%	-28.6%	-40.78%	-29.28%	-43.4%	20.08%	8.44%	260.61%
Total Assets	$35.29B	$30.28B	$24.63B	$21.14B	$15.14B	$8.461B	$6.603B	$5.238B	$3.903B	$2.867B	$1.732B	$1.693B	$1.564B	$2.482B	$2.222B	$3.259B	$3.959B	$1.805B	$1.370B	$1.272B	$1.180B	$1.583B	$1.812B	$1.946B	$83.30M
YoY Change
Accounts Payable	$330.0M	$245.0M	$350.0M										$33.50M	$32.80M	$44.80M	$91.00M	$76.90M	$47.40M	$14.50M	$15.80M	$24.00M	$94.60M	$28.30M	$13.80M	$2.100M
YoY Change	34.69%	-30.0%											2.13%	-26.79%	-50.77%	18.34%	62.24%	226.9%	-8.23%	-34.17%	-74.63%	234.28%	105.07%	557.14%
Accrued Expenses	$637.0M	$481.0M	$296.0M												$87.10M
YoY Change	32.43%	62.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$90.00M	$74.00M	$62.00M	$42.00M	$26.00M			$0.00	$118.0K	$0.00	$2.100M	$3.800M	$5.800M	$6.100M	$7.000M	$5.700M	$7.500M	$7.000M	$8.600M	$8.000M	$17.10M	$16.80M	$16.20M	$15.20M	$0.00
YoY Change	21.62%	19.35%	47.62%	61.54%				-100.0%		-100.0%	-44.74%	-34.48%	-4.92%	-12.86%	22.81%	-24.0%	7.14%	-18.6%	7.5%	-53.22%	1.79%	3.7%	6.58%
Total Short-Term Liabilities	$2.484B	$1.823B	$1.568B	$1.253B	$938.0M	$443.3M	$327.1M	$411.5M	$414.4M	$656.0M	$907.5M	$1.184B	$976.7M	$1.325B	$894.3M	$1.057B	$1.067B	$185.8M	$237.2M	$70.00M	$75.10M	$160.4M	$69.80M	$37.70M	$2.400M
YoY Change	36.26%	16.26%	25.14%	33.58%	111.57%	35.53%	-20.51%	-0.69%	-36.83%	-27.72%	-23.33%	21.19%	-26.26%	48.12%	-15.37%	-0.99%	474.43%	-21.67%	238.86%	-6.79%	-53.18%	129.8%	85.15%	1470.83%
Long-Term Debt	$680.0M	$523.0M	$363.0M	$277.0M	$155.0M	$0.00	$0.00	$0.00	$0.00	$118.0K	$400.0K	$1.900M	$6.100M	$11.80M	$17.90M	$9.000M	$8.200M	$11.30M	$14.50M	$21.00M	$18.60M	$23.60M	$29.90M	$40.80M	$0.00
YoY Change	30.02%	44.08%	31.05%	78.71%					-100.0%	-70.5%	-78.95%	-68.85%	-48.31%	-34.08%	98.89%	9.76%	-27.43%	-22.07%	-30.95%	12.9%	-21.19%	-21.07%	-26.72%
Other Long-Term Liabilities	$515.0M	$491.0M	$500.0M	$492.0M	$3.000M	$3.290M	$3.629M	$0.00	$1.433M	$177.7M	$164.1M	$124.2M	$95.20M	$65.10M	$12.10M	$4.700M
YoY Change	4.89%	-1.8%	1.63%	16300.0%	-8.81%	-9.34%		-100.0%	-99.19%	8.26%	32.13%	30.46%	46.24%	438.02%	157.45%
Total Long-Term Liabilities	$1.195B	$1.014B	$863.0M	$769.0M	$158.0M	$3.290M	$3.629M	$0.00	$1.433M	$177.8M	$164.5M	$126.1M	$101.3M	$76.90M	$30.00M	$13.70M	$8.200M	$11.30M	$14.50M	$21.00M	$18.60M	$23.60M	$29.90M	$40.80M	$0.00
YoY Change	17.85%	17.5%	12.22%	386.71%	4702.43%	-9.34%		-100.0%	-99.19%	8.07%	30.45%	24.48%	31.73%	156.33%	118.98%	67.07%	-27.43%	-22.07%	-30.95%	12.9%	-21.19%	-21.07%	-26.72%
Total Liabilities	$3.679B	$2.837B	$2.431B	$2.022B	$1.096B	$446.6M	$330.8M	$411.5M	$415.8M	$833.7M	$1.072B	$1.310B	$1.078B	$1.402B	$924.3M	$1.070B	$1.076B	$197.0M	$251.7M	$90.90M	$93.70M	$184.0M	$99.70M	$78.50M	$2.400M
YoY Change	29.68%	16.7%	20.23%	84.49%	145.39%	35.04%	-19.63%	-1.03%	-50.13%	-22.23%	-18.15%	21.49%	-23.08%	51.63%	-13.65%	-0.47%	445.94%	-21.73%	176.9%	-2.99%	-49.08%	84.55%	27.01%	3170.83%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $122.52 Billion

About GENMAB A/S

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Industry: Pharmaceutical Preparations Peers: Ascendis Pharma A/S IO Biotech, Inc.